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Abstract
Background: KRAS mutations may predict poor response to radiotherapy. Downstream events from KRAS, such as
activation of BRAF, AKT and ERK, may also confer prognostic information but have not been tested in rectal cancer
(RC). Our objective was to explore the relationships of KRAS and BRAF mutation status with p-AKT and p-ERK and
outcomes in RC.
Methods: Pre-radiotherapy RC tumor biopsies were evaluated. KRAS and BRAF mutations were assessed by
pyrosequencing; p-AKT and p-ERK expression by immunohistochemistry.
Results: Of 70 patients, mean age was 58; 36% stage II, 56% stage III, and 9% stage IV. Responses to neoadjuvant
chemoradiotherapy: 64% limited, 19% major, and 17% pathologic complete response. 64% were KRAS WT, 95%
were BRAF WT. High p-ERK levels were associated with improved OS but not for p-AKT. High levels of p-AKT and
p-ERK expression were associated with better responses. KRAS WT correlated with lower p-AKT expression but not
p-ERK expression. No differences in OS, residual disease, or tumor downstaging were detected by KRAS status.
Conclusions: KRAS mutation was not associated with lesser response to chemoradiotherapy or worse OS. High
p-ERK expression was associated with better OS and response. Higher p-AKT expression was correlated with better
response but not OS.
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Background
The most common genetic mutation in all cancers is the
RAS mutation, occurring in 30% of cancers [1]. The RAS
family of genes (K-, H-, and N-RAS) transduce, and likely
integrate, messages from growth factor receptors [2].
Intracellular pathway signaling via the RAS pathway
causes cell proliferation and invasion along with evasion
of apoptosis [2,3]. In rectal cancer (RC) series that
included patients with stage IV disease, KRAS mutations,
are reported in 19 to 48% of patients[4-6]. This is similar
to metastatic colorectal cancer (mCRC) in which muta-
tions are found in 30 to 40% of patients, mostly at codons
12, 13, and 61. Mutation of these codons of KRAS leads
to constitutive activation of the RAS signaling pathway.
There are conflicting data with regards to the predictive
and prognostic significance of KRAS mutations in colon
cancer, and less is known for RC. However, in an initial
assessment of RAS oncogene expression in RC, one retro-
spective study evaluated the RAS gene protein product,
p21 [7]. Higher p21 titers were associated with worse 5
year survival (44 vs. 64%, p < 0.02), more frequent distant
metastases (52 vs. 23%, p < 0.001), and more advanced
stage (54 vs. 36% incidence of Dukes’ C, p < 0.04) [7].
RAF is one of several targets of activated RAS, and itself
is mutated in approximately 8 to 10% of mCRC,[8] and 0
to 12% specifically in RC [5,6,9,10]. There is strong evi-
dence to suggest that KRAS and BRAF mutations are
mutually exclusive [8,11-13]. Constitutive activation of
BRAF leads to extracellular signal-regulated kinase (ERK)
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required for cell proliferation and allows for the evasion
of apoptosis [14]. To date, only small studies have been
reported in mCRC, but these suggest that outcomes are
worse among patients with BRAF mutations [8,13]. In
RC, this has not been corroborated and the effect(s) of
ERK has not been elucidated.
The phosphatidylinositol 3-kinase (PI3K)/AKT path-
way is another downstream activation target of mutated
KRAS, and is important in cell metabolism, growth, moti-
lity, survival, proliferation, and metastasis [15-18]. Fol-
lowing activation through receptor kinases or activated
RAS, PI3K phosphorylates and activates AKT (pAKT)
[19]. Activation of AKT by PI3K is inhibited by the
tumor suppressor gene PTEN,[19] which is occasionally
lost via mutation or gene silencing in CRC [20,21]. In
small cell lung cancer, elevated phosphorylated AKT was
associated with limited stage disease but was not prog-
nostic [22]. In prostate cancer, AKT expression intensity
has been associated with serum levels of prostate specific
antigen [23]. In breast cancer, p-AKT expression was
inversely correlated with survival [24]. Ionizing and UV
radiation are known to activate the PI3K/AKT pathway
[25]. Activating mutations of the PI3K p110 subunit are
found in 10 to 30% of colon cancers [17,26,27]. In
mCRC, it is not clear if mutation of PI3K or activation of
the pathway has an impact on survival or other outcomes
[19,26].
Based on the above preclinical and clinical findings, the
objective of this study was to explore the relationships of
KRAS and BRAF status with p-AKT and p-ERK expression
and with clinical outcomes (response to radiation and
overall survival [OS]) in rectal adenocarcinoma. Many
downstream targets of RAS can be inhibited by small
molecule agents, yet potential consequences of such inhi-
bition are not known. The principal rationale was to deter-
mine which RAS-activated pathways are relevant to
radiation (RT) resistance in order to select appropriate
targets for therapy. Both KRAS and BRAF mutations were
hypothesized to confer radioresistance and result in lesser
response to RT and worse survival. Activation of either
AKT or ERK was also hypothesized to antagonize chemor-
adiotherapy effects, be associated with worse survival, and
be associated with mutations of KRAS or BRAF.
Methods
This was a retrospective study of RC patients identified
through the Institutional Tumor Registry, who received
preoperative chemoradiotherapy with concurrent 5FU
chemotherapy followed by surgical resection, and had
adequate tissue for evaluation in the preoperative biopsy
and/or surgical resection sample. Clinical data were col-
lected from the patients’ medical records with complete
follow-up until April 23, 2008, at which point survival
data were censored. Conduct of the study was performed
with approval by our Institutional Review Board and in
accordance with the Helsinki Declaration of 1975, as
revised in 2000.
The primary clinical outcome measure for this study
was pathologic response, which was divided into three
objective categories: limited response (pLR, gross resi-
dual disease present), major response (pMR, only micro-
scopically visible disease remaining), or complete
response (pCR, no pathologic evidence of residual
tumor cells). AJCC pathologic stage at surgery was also
assessed and compared with preoperative staging to
determine treatment response (downstaging).
Mutation analysis
KRAS and BRAF mutation testing were performed by
pyrosequencing as described elsewhere,[28-31] using pre-
operative or postoperative samples. All samples were
enriched for tumor cells by microdissection prior to
mutation testing. An H&E stained slide prepared from
formalin-fixed paraffin embedded tissue samples was
examined under a light microscope by a pathologist and
an area containing at least 50% tumor cells was microdis-
sected from adjacent unstained slides for tumor enrich-
ment prior to xylene deparaffinization and DNA
extraction. DNA was extracted using the Qiagen DNeasy
Tissue Extraction Kit from tissue samples pretreated with
xylene for removal of paraffin. Pyrosequencing was per-
formed to identify KRAS mutations in codons 12, 13 and
61 and the BRAF V600E mutation using the PyroMark
Q96 KRAS v2.0 kit (#972452, Qiagen) and PyroMark
BRAF RUO Kit (#40-0057, Qiagen), respectively, as per
the manufacturer instructions. PCR reactions were per-
formed on a Veriti thermal cycler (Applied Biosystems)
and pyrosequencing was performed on the PyroMark
MD (Pyrosequencing AB). A positive control, normal
control, and blank (no DNA template) PCR control were
included in each assay. Pyrograms were analyzed by
PyroMark 1.0 software using allele quantification (AQ)
mode to determine the percentage of mutant versus
wild-type alleles according to relative peak height.
Immunohistochemistry (IHC)
was performed on preoperative biopsies using previously
published methods [32]. Briefly, unstained 5-micron-thick
sections were baked at 60°C for 15 to 60 minutes. Baked
sections were soaked twice in fresh xylene for 5 minutes
each, then soaked in 100% ethanol for 3 minutes, and
blocked for endogenous peroxidase with 3% hydrogen per-
oxide in methanol for 10 minutes. Slides were soaked in
95% ethanol for 3 minutes, 70% ethanol for 3 minutes,
rinsed in distilled water and soaked in Dako wash buffer
(Dako Cat. No. S3006; Dako, Glostrup, Denmark) for
5 minutes. Slides were then steamed in a Black & Decker
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(Dako) for each primary antibody to be studied (Ser-473
antibody for p-AKT, Cell Signaling Systems, Cat. No.
736E11; Thr-202/Tyr-204 antibody for p-ERK, Cell Signal-
ing Systems, Ca. No. D13.14.4E) and then allowed to cool
for at least 20 minutes. Sections were transferred to Dako
wash buffer for 5 minutes. Endogenous biotin was neutra-
lized by incubating the slides in a biotin blocking system
(Dako Cat. No. X0590) for 10 minutes at room tempera-
ture in each of the 2 solutions. Sections were then exposed
to the primary antibodies (Ser-473 antibody at 1:25 dilu-
tion; Thr-202/Tyr-204 antibody at 1:200 dilution) for 30
minutes at room temperature. After rinsing in Dako wash
buffer, slides were incubated with the Dako LSAB2 bioti-
nylated link for 10 minutes at room temperature, rinsed in
Dako wash buffer, and then incubated with the Dako
LSAB2 streptavidin-horseradish peroxidase for 10 minutes
at room temperature. After additional rinsing in Dako
wash buffer, detection of the antibody/antigen complex
was visualized using 3-3 diaminobenzidine for 5 minutes.
Slides were then rinsed in water, lightly counterstained in
filtered Mayer’s hematoxylin, rinsed, dehydrated, cleared,
and mounted. The cells of interest (tumor cells) in each
section were scored for percentage reactivity and signal
strength in both the cytoplasm and the nuclei. Simulta-
neously stained normal rectal mucosa and no primary
antibody stained normal mucosa served as negative con-
trols in each experiment.
Nuclear peroxidase staining (chosen because it was
more consistent from sample to sample than cytoplasmic
staining) was scored by one surgical pathologist (WKF)
who was blinded to clinical information. Sections were
scored by multiplying the average staining intensity seen
on a scale of 0 to 3+ by the percentage of cells that were
positive to any degree, creating a range of possible scores
of 0 to 300.
Statistical Methods
Categorical data were analyzed using Fisher’s Exact Test.
Continuous data comparing pathological response and
stage with p-AKT and p-ERK activation used Jonckheere-
Terpstra tests to account for ordered differences among
groups, and Wilcoxon Rank Sum tests were used to com-
pare p-AKT and p-ERK among mutation groups. Survival
curves were created using the Kaplan Meier method and
were compared using the Log rank test; OS was calculated
from the time of radiation treatment. Cox regression ana-
lyses were used to explore the association of p-AKT and
p-ERK activation with OS. Analyses were performed using
SAS v9.2 statistical software.
Results
Patient characteristics are summarized in Table 1 (n = 70).
Six patients (9%) had stage IV disease at diagnosis for
which initial treatment with chemoradiotherapy was
selected. At the time of surgery, 43% of patients were
downstaged and 17% had a pCR. All but two patients
received concurrent 5-FU chemotherapy with the radia-
tion. There was no association of age, sex, nor race with
stage at diagnosis (all p > 0.2).
With a median follow-up for survivors of 42 months,
36% experienced recurrence, 72% of which were distant
recurrences. For all patients, the median OS was 4.5
years (95% CI 3.0-12.5).
KRAS and BRAF mutation testing was successfully
performed on 67 and 64 of the tumors, respectively.
Among evaluable samples, 24 (36%) were mutant for
KRAS and 3 (5%) were mutant for BRAF (Table 2).
KRAS and BRAF mutations were mutually exclusive
except in one patient (who had a pCR and therefore
further tissue was not available) in which the tumor was
positive for both KRAS and BRAF mutations.
KRAS/BRAF mutations do not predict chemoradiation
response in rectal cancer
One of our principal hypotheses based on preclinical
information was that KRAS mutation would confer
radioresistance and result in reduced response to RT.
Our results, however, did not confirm this hypothesis
(Table 2). There was no difference in residual tumor
Table 1 Patient characteristics and clinical data
Characteristics N = 70
Age at diagnosis Median 58 years
Range 26-89
Gender Male 42 (60%)
Female 28 (40%)
Race White 52 (74%)
Black 15 (21%)
Other or unknown 3 (4%)
Clinical disease stage (at diagnosis) II 25 (36%)
III 39 (56%)
IV 6 (9%)
Pathological disease response Complete response (pCR) 12 (17%)
Major response (pMR) 13 (19%)
Limited response (pLR) 45 (64%)
Treatment response Downstaged 30 (43%)
No change 33(47%)
Upstaged 7 (10%)
Recurrence No 45 (64%)
Yes 25 (36%)
Local recurrence 7 (10%)
Distant recurrence 13 (19%)
Both local and distant 5 (7%)
Status (censored April 23, 2008) Alive 41 (59%)
Dead 29 (41%)
pCR: Complete response; pMR: Major response; pLR: Limited response.
Davies et al. Radiation Oncology 2011, 6:114
http://www.ro-journal.com/content/6/1/114
Page 3 of 9status, difference in radiation response as assessed by
downstaging of tumors, or frequency of local recurrence
based on KRAS or BRAF status.
KRAS/BRAF mutations do not predict overall survival in
rectal cancer
There was no difference in OS by KRAS mutation status
(median OS 4.1 years for WT vs. 4.9 years for mutated
tumors, p = 0.6, Table 2), consistent with recent results
in mCRC [33]. The number of patients with BRAF
mutation was small and we did not find a significant dif-
ference in OS by BRAF mutation status (median OS 4.1
years for WT vs. not reached for mutated tumors, p =
0.1). Interestingly, none of the three BRAF mutant
patients died during follow-up, a finding that is limited
given the small number of patients.
AKT activation status, but not ERK activation status,
correlates with KRAS mutation status
Because ERK and AKT are both potential targets of acti-
vated/mutated KRAS, we explored correlations between
KRAS mutation and phosphorylation status of these
molecules. Representative examples of low and high
staining intensity are demonstrated for pAKT and pERK
(Figure 1). Median nuclear p-AKT staining intensity was
80 (range 0-300). Patients with mutant KRAS tumors had
higher p-AKT scores (mean = 109) than KRAS WT
tumors (mean = 67, p = 0.04, Figure 2A). Median nuclear
p-ERK staining intensity was 80 (range 0-300). Surpris-
ingly, and in contrast to p-AKT, there was no difference
noted in p-ERK intensity by KRAS mutation status (p =
0.5, Figure 2B). No significant association was noted
between p-ERK levels and BRAF mutational status in this
small group of patients.
p-AKT and p-ERK activation are associated with better
response to chemoradiotherapy
Based on existing preclinical information, we hypothe-
sized that activation of either AKT or ERK would antago-
nize chemoradiotherapy effect based on inhibition of
apoptosis [34,35]. To test this, we examined associations
between p-AKT or p-ERK activation status defined by
IHC with chemoradiotherapy response and survival. Our
results stand in contradiction to our hypothesis, however,
in that increasing intensity of both p-AKT and p-ERK
were associated with less residual disease suggestive of
better responses to RT (Figure 3). Patients with pCR or
pMR at the time of surgery had higher p-AKT levels than
those with pLR (p = 0.006). When the three pathologic
response categories were compared by p-ERK levels, dif-
ferences were noted (p = 0.02). p-ERK levels were signifi-
cantly higher in the pMR group, but not in the pCR
group, when compared to the pLR (p = 0.03, 0.07
respectively).
p-ERK activation is associated with survival, but not p-
AKT
We lastly hypothesized that either p-ERK or p-AKT acti-
vation would be associated with worse survival. On the
contrary, patients with tumor p-ERK expression above the
median had significantly longer survival compared with
those below (12.5 vs. 3.0 years, p = 0.016, Figure 4B). This
survival difference was maintained but lost statistical sig-
nificance when the stage IV patients were excluded from
the analysis (p = 0.06). Overall, for each 50 point decrease
in p-ERK staining intensity, the risk of death increased by
32% (p = 0.06), reflecting a benefit to increased p-ERK
levels. A borderline significant improvement in OS was
also detected with lesser staining intensity of p-AKT (p =
0.08, Figure 4A). When the stage IV patients were
excluded, patients with tumor p-AKT expression below
the median had significantly longer survival than those
below the median (p = 0.029).
Discussion
In RC patients treated with chemoradiotherapy, KRAS
mutation was not associated with lesser response to che-
moradiotherapy or worse OS. While both p-AKT and p-
ERK expression were correlated with better response to
chemoradiotherapy, only high p-ERK expression was
associated with better OS.
Constitutive activation of KRAS via mutation is a com-
mon finding in CRC, and one that has been assumed to
be of importance to tumorigenesis due to its frequent
and early occurrence in the adenoma-carcinoma
sequence. Recent studies in mCRC have demonstrated
Table 2 KRAS and BRAF mutational status with outcomes
KRAS (n = 67) BRAF (n = 64)
Wild-type (WT) 43 (64%) 61 (95%)
Mutant 24 (36%) 3 (5%)
Median OS WT 4.1 years 4.1 years
Median OS mutant 4.9 years p = 0.6 Not reached p = 0.1
WT vs. mutant
Limited response 67% vs. 67% 69% vs. 33% (1 of 3)
Major response 14% vs. 21% 16% vs. 0%
Complete response 19% vs. 13% p = 0.7 15% vs. 66% (2 of 3)
WT vs. mutant
Downstaged 42% vs. 38% 36% vs. 66% (2 of 3)
No change or
upstaged
58% vs. 63% p = 0.8 64% vs. 33% (1 of 3)
Recurrence
None 67% vs. 54% 62% vs. 100% (3 of 3)
Local recurrence 12% vs. 8% 10%
Distant recurrence 14% vs. 29% 20%
Both local and
distant
7% vs. 8% p = 0.5 8%
WT: Wildtype; OS: Overall Survival.
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(EGFR) inhibitors (cetuximab or panitumumab) occur
only in patients with the wild-type (WT) KRAS gene.
These drugs are now used in the treatment of mCRC,
with response rates ranging from 8% with single agent
cetuximab[36] to 23% in combination with irinotecan,
[37] and disease control rates (a combination of complete
and partial responses and stable disease) of 39 and 56%
respectively.
Preclinical studies have suggested that RAS mutation
would lead to radioresistance, and conversely that tar-
geting RAS or downstream effectors of activated KRAS
would identify potential tumor-specific radiosensitizers
[38-40]. This in part formed the rationale for targeting
of EGFR in RC, an intervention that has to date been
disappointing in clinical trials. Studies of RAS in human
RC tumor samples have generally been small and have
produced mixed conclusions [2,5,7,41-43]. These studies
have reported no change in downstaging[41] or disease
free status by KRAS status [5]. Other studies found that
KRAS WT was associated with improved survival,[2] or
trended to tumor downstaging[7] or response,[42] while
another study found associations between KRAS muta-
tion with earlier stage and better survival [43]. Our
study set out to confirm that KRAS mutational status
was associated with radiosensitivity using more modern
sequencing technology in a larger number of patients
than had been studied previously. Our findings did not
confirm KRAS mutation as a prognostic factor, nor as a
predictive factor for resistance to chemoradiotherapy,
suggesting that KRAS may not be a worthwhile target to
pursue as a radiosensitizer in RC.
Our findings confirm a relatively low rate of BRAF
mutation as is seen in mCRC, with numbers too small to
draw conclusions about the effect of BRAF on chemora-
diotherapy response. However, we note that all three
patients with confirmed BRAF mutations were long-term
survivors.
This study also represented an opportunity to assess the
effects of KRAS mutation on activation of its downstream
Figure 1 Representative examples of immunohistochemistry staining intensity for p-AKT (low intensity, panel A; high intensity, panel
B) and p-ERK (low intensity, panel C; high intensity, panel D) at 60× magnification.
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results in constitutive activation of several downstream
effectors, and to date it has not been clear which effectors
are most important in mediating the effects of mutated
KRAS in cancer cells [1]. We found that AKT activation
was significantly associated with KRAS activation, while
ERK activation was not. One potential weakness of this
finding, however, is that anti-phosphoprotein antibodies
were used in paraffin-embedded tissues of various ages
with the possibility that there was variability in the stability
of the phosphorylated proteins. Another small study of
predominantly stage II and III CRC tumors evaluated the
KRAS/BRAF/ERK pathway. p-ERK was correlated with
KRAS codon 12 mutations (p = 0.016) but not with codon
13 mutations [14]. BRAF mutations (V599) were infre-
quent (8.7%) and not associated with p-ERK status [14].
We did not examine the association between mutation
location and p-ERK in our study. Preoperative sample lim-
itations prevented all phosphorylation and mutational ana-
lyses to be conducted on these untreated samples.
Among our most interesting findings was that higher
p-ERK levels were associated with better survival and
A B
Figure 2 p-AKT (A; wildtype n = 41, mutant n = 24) and p-ERK (B; wildtype n = 42, mutant n = 23) expression by KRAS mutational
status.
AB
Figure 3 p-AKT (A; pLR n = 43, pMR n = 13, pCR n = 12) and p-ERK (B; pLR n = 44, pMR n = 12, pCR n = 12) expression by radiation
response (residual disease at the time of surgery) with responses categorized as limited response (pLR), major response (pMR), or
complete response (pCR).
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expression was also associated with better response to
chemoradiotherapy. Certain tumors exhibiting activated
AKT, including squamous cell cancer of the head and
neck[44] and cervical cancer,[34] have been shown to
respond poorly to chemoradiotherapy. The positive
association between ERK activation and response is less
surprising, as ERK activation results in increased cell
cycling,[45] and presence of higher fractions of cycling
cells has previously been associated with better outcome
from chemoradiotherapy for RC [46]. The positive asso-
ciation between ERK activation and survival is the first
described in RC to our knowledge. In hepatocellular car-
cinoma, higher pERK staining intensity was associated
with longer time to progression [47].
It is more difficult to understand why AKT activation
would be beneficial in terms of response. Data from
other tumor types suggests that activation of the AKT
cell survival pathway confers resistance to radiation
[34,44]. For example, in a PTEN-deficient glioma model,
a case in which AKT is constitutively active, PTEN gene
transfer resulted in significant radiosensitization [48]. In
a recent publication, it was demonstrated that PI3K
mutations, which would be expected to result in constitu-
tive AKT activation, were associated with a higher rate of
local recurrence of RC (27.8 vs. 9.4%) [6].
Conclusions
In summary, we assessed RAS and selected downstream
effectors in order to determine the relationships
between KRAS (and BRAF) with these effectors and clin-
ical outcomes. Our results suggest that activation of
AKT and ERK may be beneficial for response to radia-
tion therapy, and thus targeting these pathways in the
setting of chemoradiotherapy could possibly be contra-
indicated and should be evaluated prospectively with a
sufficient sample size.
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